scholarly journals Prognostic significance of anti-diabetic medications in pancreatic cancer: A meta-analysis

Oncotarget ◽  
2017 ◽  
Vol 8 (37) ◽  
pp. 62349-62357 ◽  
Author(s):  
Dong-Chu Zhou ◽  
Hui Gong ◽  
Chong-Qing Tan ◽  
Jian-Quan Luo
Keyword(s):  
Pancreatic Cancer ◽  
Meta Analysis ◽  
Prognostic Significance

The clinicopathological and prognostic significance of PD-L1 expression in pancreatic cancer: A meta-analysis

2018 ◽  
Vol 17 (2) ◽  
pp. 95-100 ◽  
Author(s):  
He-Li Gao ◽  
Liang Liu ◽  
Zi-Hao Qi ◽  
Hua-Xiang Xu ◽  
Wen-Quan Wang ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Meta Analysis ◽  
Prognostic Significance

scholarly journals The prognostic value of modified Glasgow Prognostic Score in pancreatic cancer: a meta-analysis

2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Huan Zhang ◽  
Dianyun Ren ◽  
Xin Jin ◽  
Heshui Wu
Keyword(s):  
Pancreatic Cancer ◽  
Prognostic Value ◽  
Close Association ◽  
Meta Analysis ◽  
Prognostic Score ◽  
Prognostic Significance ◽  
Glasgow Prognostic Score ◽  
Cochrane Library ◽  
Modified Glasgow Prognostic Score ◽  
High Level

Abstract Background Several studies were conducted to explore the prognostic value of modified Glasgow Prognostic Score (mGPS) in pancreatic cancer, which reported contradictory results. The purpose of this meta-analysis was to summarize and further investigate the correlation between mGPS and overall survival (OS) in pancreatic cancer. Methods A systematic literature search was performed in PubMed, EMBASE, ISI Web of Science, Cochrane library databases and OVID to identify eligible studies published from Jan 1, 2011 to June 20, 2020. Pooled hazard ratios (HRs) with corresponding 95% confidence intervals (CIs) were used to detect the prognostic significance of mGPS in patients with pancreatic cancer. Results A total of 222 non-repetitive studies were identified, and 20 related studies that explored the association between survival outcomes and mGPS in pancreatic cancer patients were finally enrolled in this meta-analysis. The results showed a significant correlation between high level of mGPS and poor OS (HR = 1.50, 95% CI 1.20–1.89, P < 0.0001). Similar results were observed in the subgroup analyses based on the treatment regimen and research region. Conclusions Our study suggested the close association between poor prognosis and high level of mGPS, which will be helpful for future clinical applications in patients with pancreatic cancer.

scholarly journals Prognostic Significance of the Modified Glasgow Prognostic Score in Patients With Pancreatic Cancer: A Meta-Analysis

Dose-Response ◽  
2020 ◽  
Vol 18 (3) ◽  
pp. 155932582094206
Author(s):  
Wen Fu ◽  
Kun Wang ◽  
Shan Yan ◽  
Xie Wang ◽  
Bo Tang ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Meta Analysis ◽  
Prognostic Score ◽  
Prognostic Significance ◽  
Glasgow Prognostic Score ◽  
Disease Free Survival ◽  
Cochrane Library ◽  
Survival Outcomes ◽  
Free Survival ◽  
Modified Glasgow Prognostic Score

Background: The prognostic value of the modified Glasgow prognostic score (mGPS) in patients with pancreatic cancer is controversial, based on previous studies. Therefore, this meta-analysis aimed to explore the relationship between mGPS and prognosis in pancreatic cancer. Methods: The databases PubMed, Web of Science, Embase, and the Cochrane Library were searched to identify eligible studies. Hazard ratios (HRs) and 95% confidence intervals (CIs) were used to estimate the associations between mGPS score and survival outcomes. Results: A total of 26 studies with 5198 patients were included in this meta-analysis. In a pooled analysis, elevated mGPS predicted poorer overall survival (OS; HR = 1.98, 95% CI, 1.65-2.37, P < .001). In addition, elevated mGPS was also significantly associated with worse progression-free survival (PFS), disease-free survival (DFS), and cancer-specific survival (CSS; HR = 1.95, 95% CI, 1.36-2.80, P < .001). Subgroup analyses confirmed a significant association between mGPS and survival outcomes. Conclusions: Our meta-analysis demonstrated that high mGPS was correlated to worse OS, PFS, DFS, and CSS in patients with pancreatic cancer. Therefore, mGPS could be employed as an effective prognostic factor for pancreatic cancer in clinical practice.

scholarly journals The Prognostic Value of Modified Glasgow Prognostic Score in Pancreatic Cancer: A Meta-analysis

2020 ◽  
Author(s):  
Huan Zhang ◽  
Dianyun Ren ◽  
Xin Jin ◽  
Heshui Wu
Keyword(s):  
Pancreatic Cancer ◽  
Prognostic Value ◽  
Close Association ◽  
Meta Analysis ◽  
Prognostic Score ◽  
Prognostic Significance ◽  
Glasgow Prognostic Score ◽  
Cochrane Library ◽  
Modified Glasgow Prognostic Score ◽  
High Level

Abstract Background: Several studies were conducted to explore the prognostic value of modified Glasgow Prognostic Score (mGPS) in pancreatic cancer, which reported contradictory results. The purpose of this meta-analysis was to summarize and further investigate the correlation between mGPS and overall survival (OS) in pancreatic cancer.Methods: A systematic literature search was performed in PubMed, EMBASE, ISI Web of Science, Cochrane library databases and OVID to identify eligible studies published from Jan 1, 2011 to June 20, 2020. Pooled hazard ratios (HRs) with corresponding 95% confidence intervals (CIs) were used to detect the prognostic significance of mGPS in patients with pancreatic cancer.Results: A total of 222 non-repetitive studies were identified, and 20 related studies that explored the association between survival outcomes and mGPS in pancreatic cancer patients were finally enrolled in this meta-analysis. The results showed a significant correlation between high level of mGPS and poor OS (HR=1.50, 95% CI=1.20-1.89, P<0.0001). Similar results were observed in the subgroup analyses based on the treatment regimen and research region.Conclusions: Our study suggested the close association between poor prognosis and high level of mGPS, which will be helpful for future clinical applications in patients with pancreatic cancer.

Prognostic significance of cyclooxygenase-2 protein in pancreatic cancer: a meta-analysis

Tumor Biology ◽  
2014 ◽  
Vol 35 (10) ◽  
pp. 10301-10307 ◽  
Author(s):  
Di Wang ◽  
Xiao-Zhong Guo ◽  
Hong-Yu Li ◽  
Jia-Jun Zhao ◽  
Xiao-Dong Shao ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Meta Analysis ◽  
Prognostic Significance ◽  
Cyclooxygenase 2

scholarly journals Prognostic significance of K-ras mutations in pancreatic cancer: a meta-analysis

2016 ◽  
Vol 14 (1) ◽  
Author(s):  
Lian-yuan Tao ◽  
Ling-fu Zhang ◽  
Dian-rong Xiu ◽  
Chun-hui Yuan ◽  
Zhao-lai Ma ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Meta Analysis ◽  
Prognostic Significance ◽  
Ras Mutations

scholarly journals The Prognostic Value of Modified Glasgow Prognostic Score in Pancreatic Cancer: A Meta-analysis

2020 ◽  
Author(s):  
Huan Zhang ◽  
Dianyun Ren ◽  
Xin Jin ◽  
Heshui Wu
Keyword(s):  
Pancreatic Cancer ◽  
Cancer Patients ◽  
Prognostic Value ◽  
Close Association ◽  
Meta Analysis ◽  
Prognostic Score ◽  
Prognostic Significance ◽  
Glasgow Prognostic Score ◽  
Cochrane Library ◽  
Modified Glasgow Prognostic Score

Abstract Background: Several studies were conducted to explore the prognostic value of modified Glasgow Prognostic Score (mGPS) in pancreatic cancer, which reported contradictory results. The purpose of this meta-analysis was to summarize the prognostic value of mGPS in pancreatic cancer by investigating the correlation between mGPS and overall survival (OS). Methods: A systematic literature search was performed in PubMed, EMBASE, ISI Web of Science, Cochrane library databases and OVID to identify eligible studies published from Jan 1, 2011 to June 20, 2020. Pooled hazard ratios (HRs) with corresponding 95% confidence intervals (CIs) were used to detect the prognostic significance of mGPS in patients with pancreatic cancer. Results: A total of 222 non-repetitive studies were identified, and 20 enrolled studies described the association between survival outcomes and mGPS in pancreatic cancer patients. The results showed a significant correlation between high mGPS and poor OS (HR=1.50, 95% CI=1.20–1.89, P<0.0001). Similar results were observed in the subgroup analyses of OS, which were based on the treatment regimen and research region. Conclusions: Our study suggested the close association between the poor prognosis and high level of mGPS, which will be helpful for future clinical applications in pancreatic cancer patients.

Sign in / Sign up

Export Citation Format

Share Document